Fennec Pharmaceuticals CFO Robert Andrade said the company, which has only 3 employees, has “a great asset in a drug and a great team” and are “certainly…set up” for the potential to be sold if the FDA grants approval to its drug, Pedmark, for the prevention of hearing loss in pediatric cancer patients treated with chemotherapy, according to Seth Thomas Gulledge, a staff writer for the Triangle Business Journal. Andrade said “if need be we will build a team and do it ourselves; but obviously you can see how we’re set up right now,” according to the interview. “We’ve had a lot of interest historically from potential partners. We anticipate as we get closer to approval and to the extent we launch the drug ourselves that will continue to be one of the activities around the company,” Andrade added, according to the report.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.